BIO Announces Plenary Sessions for 11th Annual BIO Investor Forum

Sessions to focus on new pharma-VC models for biotech investing, new corporate VC models and forecasting 2013

Biotechnology Industry OrganizationAbigail Hirsch, 202-962-9230

The Biotechnology Industry Organization (BIO) announces plenary sessions for the , an international biotech investor conference focused on investment strategies for early stage and established private companies as well as emerging public companies. Hosted by , the 11 annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

“Our plenary sessions feature an esteemed group of industry analysts and investors that speak to the pressing business issues directly affecting investment in biotech,” said Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO. “Attendees have come to expect stimulating dialogue which will offer insight and guidance on how to best approach the challenges facing the industry.”

Plenary Sessions include:

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. This panel will examine what factors are driving this new model of biotech investing from both the VC and pharma standpoints and how these deals are structured.Alan F. Eisenberg, EVP, Emerging Companies & Business Development, Biotechnology Industry Organization (BIO)Francesco De Rubertis, Partner, Index Ventures; Jonathan MacQuitty, PhD, Partner, Abingworth, LP and Brian McVeigh, CPA, CMA, CLP, MBA, Vice President, WWBD Transactions & Investment Management, GlaxoSmithKline Pharmaceuticals

Funded by deep pharma pockets and an investment strategy often focused on early stage, corporate venture capital (CVC) has been a much-needed funding source for companies struggling to keep their development programs moving. The CVC model has been around since the early 1970s, but a new crop of CVCs has sprouted in recent years. A panel of leading CVCs will explore how the CVC model has changed over time and whether these changes measure up to the tried and true models.Joseph S. Dillon, CLP, Managing Director, Investor Relations & Business Development, Biotechnology Industry Organization (BIO): Jeff Calcagno, MD, Senior Director, Emerging Technologies, California Innovation Center, Johnson & Johnson: Lauren Silverman, PhD, Managing Director, Novartis Option Fund; Ron Laufer, MD, MPH, Senior Managing Director, MedImmune Ventures and Geeta Vemuri, PhD, Senior Managing Director, Baxter Ventures

Seasoned biotech investors engage in a candid and insightful discussion on what the industry can expect in 2013. Topics to be covered include: IPO markets; big pharma acquisitions and their effect on the biotech pipeline and early-stage funding sources. Joel Sendek, Managing Director, Head Healthcare Equity Research, Stifel Nicolaus: Srini Akkaraju, PhD, MD, Managing Director, New Leaf Venture Partners; Evan McColloch, Portfolio Manager, Franklin Templeton Investments; Bryan Roberts, PhD, Partner, Venrock and Asish Xavier, PhD, Vice President, Johnson & Johnson Development Corporation

In addition to Plenary Sessions, the Investor Forum will feature Business Roundtables which will take a closer look at both early stage financing and late stage exit strategies for private companies.

Business Roundtables include:

Tuesday, October 9, 9:00 a.m. – 9:55 a.m.Although venture capital financing continues to decrease in the life sciences, the dearth in capital has spawned a new team of funders that are stepping up to the plate to fill the gap. Panelists will discuss what unique experiences these new players bring and how they will impact and improve the drug development process.: Jeron Eaves, Senior Practice Executive, Campbell Alliance: Lindy Fishburne, Executive Director, Breakout Labs, Thiel Foundation; Mark Goldsmith, MD, PhD, Venture Partners, Third Rock Ventures; Walter C. Ogier, President & CEO, Acetylon Pharmaceuticals, Inc and Robert Sarisky, PhD, Chief Business Officer, Forma Therapeutics, Inc.

Wednesday, October 10, 9:00 a.m. – 9:55 a.m.A promising company that is no longer a start-up and has secured series C states us often faced with the question…now what? Experienced decision makers that have navigated the exit strategy crossroads will discuss the lessons learned and how this year’s developments could affect exit strategies.: Peter Reikes, Vice Chairman, Healthcare Investment Banking, Stifel Nicolaus Weisel: Mark Leuchtenberger, President & CEO, Rib-X Pharmaceuticals, Inc; Dennis Purcell, Senior Managing Partner, Aisling Capital; Todd Smith, EVP, Chief Commercial Officer, Horizon Pharma and Timothy Trost, CPA, SVP & CFO, Chimerix, Inc.

The features public and venture-stage company presentations, expert-led therapeutic workshops on the latest market and investment opportunities with emphasis on drug and technology development, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit . Advance media registration is available . Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces , an online portal and monthly newsletter chronicling “innovations transforming our world.” .

October 9-10, 2012San Francisco, CA

October 10-12, 2012Vancouver, Canada

October 24-25, 2012Shanghai, China

November 12-14, 2012Charleston, SC

January 29 – 30, 2013Tokyo, Japan

February 11 – 12, 2013New York City, NY

April 22 – 25, 2013Chicago, IL

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.